Pfizer 3Q Revenues: $13.2 billion (+1%) 3Q Earnings: $2.7 billion (+110%) YTD Revenues: $38.8 billion (+1%) YTD Earnings: $9.0 billion (+40%) Comments: Innovative Health sales in the quarter were $8.1 billion, up 11%, with growth from key brands including Ibrance and Eliquis, the addition of Xtandi revenues in the U.S. from the September 2016 acquisition of Medivation, as well as Lyrica and Xeljanz, primarily in the U.S. Global Ibrance revenues increased 59% operationally while global opera...